Sat, Dec 20, 2014, 9:28 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • xwavve xwavve Nov 7, 2013 9:24 AM Flag

    Front-line HL ORR 82 Percent: Compelling

    In this interim analysis of patients aged ≥60 years with newly diagnosed HL, compelling antitumor activity with single-agent brentuximab vedotin has been demonstrated. To date, a response rate of 82% has been shown in this historically challenging population of patients who either declined or were not eligible for standard chemotherapy. Preliminary safety data demonstrate tolerability in this patient population and the data are consistent with the current safety profile of brentuximab vedotin.

32.89-0.15(-0.45%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.